General Inhibitors

By Targets:	11β-HSD (1) Amyloid-β (1) Autophagy (2) Bacterial (1) Cathepsin (1) Eukaryotic Initiation Factor (eIF) (1) FAK (1) HIV (1) PI3K (1) PKC (2) Poly(ADP-ribose) Glycohydrolase (PARG) (2)
By Research Areas:	Cancer (7) Infection (1) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15282

E-64 5+ Cited Publications Proteinase inhibitor E 64	Cathepsin Autophagy Bacterial	Inflammation/Immunology Cancer
E-64 (Proteinase inhibitor E 64) is a potent irreversible inhibitor against general cysteine proteases with IC₅₀ of 9 nM for papain.

HY-112654

GCN2iB Maximum Cited Publications 23 Publications Verification	Eukaryotic Initiation Factor (eIF) Autophagy	Cancer
GCN2iB is an ATP-competitive inhibitor of a serine/threonine-protein kinase general control nonderepressible 2 (GCN2), with an IC₅₀ of 2.4 nM.

HY-100877

GCN2-IN-1 10+ Cited Publications A-92
GCN2-IN-1 (A-92) is a potent general control nonderepressible 2 kinase (GCN2) inhibitor with an IC₅₀ of <0.3 μM in the enzyme assay and an IC₅₀ of 0.3-3 μM in the cell assay .

HY-151460

GCN2-IN-7	Others	Cancer
GCN2-IN-7 (compound 39) is an orally active and selective general control nonderepressible 2 (GCN2) inhibitor (IC₅₀=5 nM). GCN2-IN-7 shows anti-tumor activity in vivo .

HY-108604

Bisindolylmaleimide II

Bis II
PKC Metabolic Disease Cancer

Bisindolylmaleimide II is a general inhibitor of all PKC subtypes .

Bisindolylmaleimide II Bis II	PKC	Metabolic Disease Cancer
Bisindolylmaleimide II is a general inhibitor of all PKC subtypes .

HY-146248B

TFMU-ADPr diammonium	Others	Metabolic Disease
TFMU-ADPr is a universal substrate for monitoring PARG activity. TFMU-ADPr directly reports the total bar number hydrolase activity by releasing fluorophore. TFMU-ADPr is a general tool for evaluating small molecule inhibitors and exploring the regulation of ADP-ribose catabolic enzymes in vitro .

HY-145652

Narmafotinib AMP-945	FAK	Cancer
Narmafotinib (AMP-945) is an inhibitor of the enzyme focal adhesion kinase (FAK, K_D=0.21 nM). Narmafotinib inhibits autophosphorylation of 397Y-FAK in MDA-MB-231 cells with an IC₅₀=7 nM and exhibits low general cellular toxicity (IC₅₀=2.7 μM, MDA-MB-231 cells) .

HY-156406

PITCOIN4	PI3K	Inflammation/Immunology
PITCOIN4 is a highly selective Class II Alpha PI3K-C2α inhibitor. PITCOIN4 shows nanomolar inhibition of PI3K-C2α and >100-fold selectivity in a general kinase panel .

HY-146248

TFMU-ADPr	Poly(ADP-ribose) Glycohydrolase (PARG)	Others
TFMU-ADPr is a general substrate for monitoring poly(ADP-ribose) glycohydrolase (PARG) activity. TFMU-ADPr can directly report on total PAR hydrolase activity via release of a fluorophore. TFMU-ADPr has excellent reactivity, generality, stability, and usability. TFMU-ADPr is a versatile tool for assessing small-molecule inhibitors in vitro and probing the regulation of ADP-ribosyl catabolic enzymes .

HY-122198

ML367	Others	Cancer
ML367 is a potent inhibitor of ATPase family AAA domain-containing protein 5 (ATAD5) stabilization, acts as a probe molecule that has low micromolar inhibitory activity. ML367 blocks DNA repair pathways, suppresses general DNA damage responses including RPA32-phosphorylation and CHK1-phosphorylation in response to UV irradiation .

HY-146248A

TFMU-ADPr triethylamine	Poly(ADP-ribose) Glycohydrolase (PARG)	Others
TFMU-ADPr triethylamine is a general substrate for monitoring poly(ADP-ribose) glycohydrolase (PARG) activity. TFMU-ADPr triethylamine can directly report on total PAR hydrolase activity via release of a fluorophore. TFMU-ADPr triethylamine has excellent reactivity, generality, stability, and usability. TFMU-ADPr triethylamine is a versatile tool for assessing small-molecule inhibitors in vitro and probing the regulation of ADP-ribosyl catabolic enzymes .

HY-B1588S

Carbenoxolone-d4	Amyloid-β HIV 11β-HSD	Infection Neurological Disease Inflammation/Immunology
Carbenoxolone-d₄ is deuterium labeled Carbenoxolone. Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties[3]. Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the research of chronic liver disease[2]. Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD[1]. Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop[4].Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that converts inactive glucocorticoid into an active form. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself[6].

HY-P5439

Epsilon-V1-2, Cys-conjugated	PKC	Others
Epsilon-V1-2, Cys-conjugated is a biological active peptide. (This peptide is the εPKC specific inhibitor. Its inhibitory activity is based on εPKC translocation and MARCKS phosphorylation. This peptide interferes with εPKC interaction with the anchoring protein εRACK. This peptide contains a cysteine residue added to the C-terminus for potential S-S bond formation with a carrier protein.Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)

Cat. No.	Product Name	Type

HY-146248

TFMU-ADPr	Chromogenic Substrates
TFMU-ADPr is a general substrate for monitoring poly(ADP-ribose) glycohydrolase (PARG) activity. TFMU-ADPr can directly report on total PAR hydrolase activity via release of a fluorophore. TFMU-ADPr has excellent reactivity, generality, stability, and usability. TFMU-ADPr is a versatile tool for assessing small-molecule inhibitors in vitro and probing the regulation of ADP-ribosyl catabolic enzymes .

TFMU-ADPr

Chromogenic Substrates

TFMU-ADPr is a general substrate for monitoring poly(ADP-ribose) glycohydrolase (PARG) activity. TFMU-ADPr can directly report on total PAR hydrolase activity via release of a fluorophore. TFMU-ADPr has excellent reactivity, generality, stability, and usability. TFMU-ADPr is a versatile tool for assessing small-molecule inhibitors in vitro and probing the regulation of ADP-ribosyl catabolic enzymes .

Cat. No.	Product Name	Target	Research Area

HY-P4806

Perisulfakinin

Peptides Neurological Disease

Perisulfakinin, a satiety signaling neuropeptide, inhibits the activity of central neurons promoting general activity .

Perisulfakinin	Peptides	Neurological Disease
Perisulfakinin, a satiety signaling neuropeptide, inhibits the activity of central neurons promoting general activity .

HY-P4102

Cyclic PSAP peptide	Peptides	Cancer
Cyclic PSAP peptide is a cyclic pentapeptide (DWLPK). Cyclic PSAP peptide exhibits agent-like properties and could inhibit metastatic spread and restrain tumor development in general in vivo .

HY-P5439

Epsilon-V1-2, Cys-conjugated	PKC	Others
Epsilon-V1-2, Cys-conjugated is a biological active peptide. (This peptide is the εPKC specific inhibitor. Its inhibitory activity is based on εPKC translocation and MARCKS phosphorylation. This peptide interferes with εPKC interaction with the anchoring protein εRACK. This peptide contains a cysteine residue added to the C-terminus for potential S-S bond formation with a carrier protein.Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)

Cat. No.	Product Name	Chemical Structure

HY-B1588S

Carbenoxolone-d4
Carbenoxolone-d₄ is deuterium labeled Carbenoxolone. Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties[3]. Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the research of chronic liver disease[2]. Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD[1]. Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop[4].Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that converts inactive glucocorticoid into an active form. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself[6].

Carbenoxolone-d4

Carbenoxolone-d₄ is deuterium labeled Carbenoxolone. Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties[3]. Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the research of chronic liver disease[2]. Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD[1]. Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop[4].Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that converts inactive glucocorticoid into an active form. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself[6].

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Fluorescent Dye

Peptides

Isotope-Labeled Compounds

Name
Email *

	Sorry, but the email address you supplied was invalid.